PT3247340T - Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas - Google Patents
Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicasInfo
- Publication number
- PT3247340T PT3247340T PT167034099T PT16703409T PT3247340T PT 3247340 T PT3247340 T PT 3247340T PT 167034099 T PT167034099 T PT 167034099T PT 16703409 T PT16703409 T PT 16703409T PT 3247340 T PT3247340 T PT 3247340T
- Authority
- PT
- Portugal
- Prior art keywords
- bdnf
- neuromuscular
- developmental
- neurodegenerative
- autoimmune
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101150035467 BDNF gene Proteins 0.000 title 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title 1
- 208000012239 Developmental disease Diseases 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 230000002232 neuromuscular Effects 0.000 title 1
- 208000018360 neuromuscular disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106365P | 2015-01-22 | 2015-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3247340T true PT3247340T (pt) | 2023-10-31 |
Family
ID=55310938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167034099T PT3247340T (pt) | 2015-01-22 | 2016-01-21 | Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9763896B2 (pt) |
| EP (2) | EP4306167A3 (pt) |
| JP (3) | JP6951976B2 (pt) |
| KR (1) | KR20170104597A (pt) |
| CN (2) | CN107405315A (pt) |
| AU (2) | AU2016209255B2 (pt) |
| BR (1) | BR112017015721A2 (pt) |
| CA (1) | CA2974092A1 (pt) |
| ES (1) | ES2961334T3 (pt) |
| HK (1) | HK1247101A1 (pt) |
| MX (2) | MX2017009402A (pt) |
| PT (1) | PT3247340T (pt) |
| WO (1) | WO2016118741A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9763896B2 (en) * | 2015-01-22 | 2017-09-19 | Mitochon Pharmaceuticals, Inc. | Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
| BR112019013371A2 (pt) | 2017-01-06 | 2019-12-10 | Rivus Pharmaceuticals Inc | novos derivados de fenila |
| KR20190124722A (ko) * | 2017-01-31 | 2019-11-05 | 파올로 엘. 만프레디 | 신경계 장애의 치료에서 사용하기 위한 ｄ-메타돈 및 이의 유도체 |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10278960B2 (en) | 2017-06-23 | 2019-05-07 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| EP4223307A1 (en) * | 2020-09-29 | 2023-08-09 | Cefo Co., Ltd. | Composition for preventing or treating neuropsychologic disease, comprising manf |
| WO2023205625A2 (en) * | 2022-04-18 | 2023-10-26 | Mitochon Pharmaceuticals, Inc. | 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP2170338A2 (en) * | 2007-07-06 | 2010-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dna-pkcs modulates energy regulation and brain function |
| CN110302385A (zh) | 2013-08-30 | 2019-10-08 | 耶鲁大学 | 新型2，4-二硝基苯酚制剂和使用其的方法 |
| US9763896B2 (en) * | 2015-01-22 | 2017-09-19 | Mitochon Pharmaceuticals, Inc. | Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
-
2016
- 2016-01-21 US US15/002,531 patent/US9763896B2/en active Active
- 2016-01-21 PT PT167034099T patent/PT3247340T/pt unknown
- 2016-01-21 EP EP23188878.5A patent/EP4306167A3/en active Pending
- 2016-01-21 CN CN201680017379.4A patent/CN107405315A/zh active Pending
- 2016-01-21 JP JP2017539363A patent/JP6951976B2/ja active Active
- 2016-01-21 KR KR1020177023034A patent/KR20170104597A/ko active IP Right Grant
- 2016-01-21 AU AU2016209255A patent/AU2016209255B2/en active Active
- 2016-01-21 MX MX2017009402A patent/MX2017009402A/es unknown
- 2016-01-21 CN CN202211548767.9A patent/CN116617195A/zh active Pending
- 2016-01-21 CA CA2974092A patent/CA2974092A1/en active Pending
- 2016-01-21 WO PCT/US2016/014312 patent/WO2016118741A1/en active Application Filing
- 2016-01-21 EP EP16703409.9A patent/EP3247340B1/en active Active
- 2016-01-21 ES ES16703409T patent/ES2961334T3/es active Active
- 2016-01-21 BR BR112017015721A patent/BR112017015721A2/pt not_active Application Discontinuation
- 2016-11-21 US US15/357,412 patent/US9974755B2/en active Active
-
2017
- 2017-07-18 MX MX2022005937A patent/MX2022005937A/es unknown
- 2017-09-18 US US15/707,239 patent/US10220006B2/en active Active
-
2018
- 2018-05-24 HK HK18106712.4A patent/HK1247101A1/zh unknown
-
2019
- 2019-01-17 US US16/250,470 patent/US10864173B2/en active Active
-
2020
- 2020-11-09 US US17/093,193 patent/US11717497B2/en active Active
-
2021
- 2021-03-01 JP JP2021031635A patent/JP7440092B2/ja active Active
- 2021-09-27 AU AU2021240120A patent/AU2021240120A1/en active Pending
-
2022
- 2022-10-03 JP JP2022159466A patent/JP2022173519A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4306167A3 (en) | 2024-03-20 |
| EP3247340A1 (en) | 2017-11-29 |
| CA2974092A1 (en) | 2016-07-28 |
| JP6951976B2 (ja) | 2021-10-20 |
| ES2961334T3 (es) | 2024-03-11 |
| US9974755B2 (en) | 2018-05-22 |
| MX2017009402A (es) | 2017-12-04 |
| EP3247340B1 (en) | 2023-08-02 |
| HK1247101A1 (zh) | 2018-09-21 |
| US20180125794A1 (en) | 2018-05-10 |
| US11717497B2 (en) | 2023-08-08 |
| JP2022173519A (ja) | 2022-11-18 |
| JP7440092B2 (ja) | 2024-02-28 |
| CN107405315A (zh) | 2017-11-28 |
| US20190142765A1 (en) | 2019-05-16 |
| US20160213625A1 (en) | 2016-07-28 |
| EP4306167A2 (en) | 2024-01-17 |
| MX2022005937A (es) | 2022-06-29 |
| KR20170104597A (ko) | 2017-09-15 |
| JP2018502898A (ja) | 2018-02-01 |
| JP2021080286A (ja) | 2021-05-27 |
| US20170065536A1 (en) | 2017-03-09 |
| US20210052513A1 (en) | 2021-02-25 |
| AU2016209255B2 (en) | 2021-07-01 |
| US9763896B2 (en) | 2017-09-19 |
| CN116617195A (zh) | 2023-08-22 |
| AU2021240120A1 (en) | 2021-10-28 |
| US10220006B2 (en) | 2019-03-05 |
| US10864173B2 (en) | 2020-12-15 |
| AU2016209255A1 (en) | 2017-08-10 |
| WO2016118741A1 (en) | 2016-07-28 |
| BR112017015721A2 (pt) | 2018-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247101A1 (zh) | 用於治療神經肌肉、神經變性、自身免疫、發育和/或代謝疾病的腦源性神經營養因子(bdnf)的誘導表達 | |
| IL282655A (en) | Methods of treating developmental disorders using pipradrol | |
| EP3389725A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| HRP20220958T8 (hr) | Sustav za liječenje oka | |
| HK1252431A1 (zh) | 用於視網膜光療的系統和方法 | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| IL269604A (en) | Pentides for the treatment of autoimmune diseases | |
| GB201507048D0 (en) | Treatment of pain | |
| EP3730144A4 (en) | AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| EP3376869A4 (en) | AUTOIMMUNE DISEASE TREATMENT | |
| HK1253901A1 (zh) | 治療或預防急性腦或神經損傷的方法 | |
| IL259381B (en) | Miravegron for the treatment of retinal diseases | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| IL274132A (en) | Treatment of skin problems | |
| GB201710105D0 (en) | Albumin-based therapeutic molecules | |
| GB201710109D0 (en) | Albumin-based therapeutic molecules | |
| HK1245069A1 (zh) | 與視網膜治療相關的改進 | |
| GB201704666D0 (en) | Treatment of neurodegenerative diseases | |
| GB201703768D0 (en) | Skin treatment methods | |
| GB201703734D0 (en) | Skin treatment methods | |
| GB201514909D0 (en) | Treatment of autoimmune diseases | |
| GB201522706D0 (en) | Treatments of central nervous system conditions |